| Entry |
|
|---|
| Name |
Sorafenib tosylate (USAN);
Sorafenib tosilate (JAN);
Nexavar (TN)
|
|---|
| Product |
|
|---|
| Formula |
C21H16ClF3N4O3. C7H8O3S
|
|---|
| Exact mass |
636.1057
|
|---|
| Mol weight |
637.0266
|
|---|
| Structure |
   |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00713): | D06272<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Disease |
Hepatocellular carcinoma [DS: H00048] Renal cell carcinoma [DS: H00021] Thyroid carcinoma [DS: H00032] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE05 Sorafenib
D06272 Sorafenib tosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Sorafenib
D06272 Sorafenib tosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06272 Sorafenib tosylate (USAN); Sorafenib tosilate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
TKL group
BRAF
D06272 Sorafenib tosylate (USAN) <JP/US>
RAF1
D06272 Sorafenib tosylate (USAN) <JP/US>
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D06272 Sorafenib tosylate (USAN) <JP/US>
KIT (CD117)
D06272 Sorafenib tosylate (USAN) <JP/US>
FLT3 (CD135)
D06272 Sorafenib tosylate (USAN) <JP/US>
VEGFR family
VEGFR2 (KDR)
D06272 Sorafenib tosylate (USAN) <JP/US>
VEGFR3 (FLT4)
D06272 Sorafenib tosylate (USAN) <JP/US>
RET family
RET
D06272 Sorafenib tosylate (USAN) <JP/US>
Antineoplastics [br08340.html]
D06272
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06272
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06272
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06272
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06272
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 43
1 C8y C 41.3134 -16.2561
2 C8x C 40.1203 -16.9579
3 C8x C 42.5767 -16.9579
4 S4a S 41.3134 -14.8525
5 C8x C 40.1203 -18.3616
6 C8x C 42.5767 -18.3616
7 O1d O 39.9098 -14.8525
8 O1d O 42.7170 -14.8525
9 O1d O 41.3134 -13.5191
10 C8y C 41.3134 -19.0634
11 C1a C 41.2961 -20.4669
12 C8x C 34.7102 -17.2381
13 C8y C 34.7102 -18.6418
14 C8x C 35.9257 -19.3436
15 C8x C 37.1414 -18.6418
16 C8y C 37.1414 -17.2381
17 C8y C 35.9257 -16.5363
18 X Cl 38.3757 -16.5253
19 C1d C 35.9257 -15.1329
20 X F 35.9383 -13.7295
21 N1b N 33.4946 -19.3436
22 C5a C 32.2961 -18.6514
23 N1b N 31.1056 -19.3387
24 O5a O 32.2960 -17.2384
25 C8y C 29.9113 -18.6489
26 C8x C 29.9113 -17.2383
27 C8x C 28.6958 -16.5365
28 C8y C 27.4802 -17.2383
29 C8x C 27.4801 -18.6488
30 C8x C 28.6957 -19.3507
31 O2a O 26.2656 -16.5369
32 C8y C 25.0675 -17.2288
33 C8x C 23.8769 -16.5413
34 C8y C 22.6613 -17.2431
35 N5x N 22.6613 -18.6468
36 C8x C 23.8519 -19.3342
37 C8x C 25.0675 -18.6324
38 C5a C 21.4269 -16.5303
39 N1b N 20.2231 -17.2254
40 O5a O 21.4271 -15.1328
41 C1a C 19.0354 -16.5396
42 X F 34.5100 -15.1267
43 X F 37.3099 -15.1389
BOND 45
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 2
5 3 6 1
6 4 7 2
7 4 8 2
8 4 9 1
9 5 10 1
10 6 10 2
11 10 11 1
12 12 13 2
13 13 14 1
14 14 15 2
15 15 16 1
16 16 17 2
17 12 17 1
18 16 18 1
19 17 19 1
20 19 20 1
21 13 21 1
22 21 22 1
23 22 23 1
24 22 24 2
25 23 25 1
26 25 26 2
27 26 27 1
28 27 28 2
29 28 29 1
30 29 30 2
31 25 30 1
32 28 31 1
33 31 32 1
34 32 33 2
35 33 34 1
36 34 35 2
37 35 36 1
38 36 37 2
39 32 37 1
40 34 38 1
41 38 39 1
42 38 40 2
43 39 41 1
44 19 42 1
45 19 43 1
|
|---|
